Abstract
Anti-PD-1 immunotherapies have transformed cancer treatment, yet the determinants of clinical response are largely unknown. We performed CODEX multiplexed tissue imaging and RNA sequencing on 70 tumor regions from 14 advanced cutaneous T cell lymphoma (CTCL) patients enrolled in a clinical trial of pembrolizumab therapy. Clinical response was not associated with the frequency of tumor-infiltrating T cell subsets, but rather with striking differences in the spatial organization and functional immune state of the tumor microenvironment (TME). After treatment, pembrolizumab responders had a localized enrichment of tumor and CD4+ T cells, which coincided with immune activation and cytotoxic PD-1+ CD4+ T cells. In contrast, non-responders had a localized enrichment of Tregs pre- and post-treatment, consistent with a persistently immunosuppressed TME and exhausted PD-1+ CD4+ T cells. Integrating these findings by computing the physical distances between PD-1+ CD4+ T cells, tumor cells, and Tregs revealed a spatial biomarker predictive of pembrolizumab response. Finally, the chemokine CXCL13 was upregulated in tumor cells in responders post-treatment, suggesting that chemoattraction of PD-1+ CD4+ T cells towards tumor cells facilitates a positive outcome. Together, these data show that T cell topography reflects the balance of effector and suppressive activity within the TME and predicts clinical response to PD-1 blockade in CTCL.
Competing Interest Statement
G.P.N. and Y.G. are co-founders and stockholders of Akoya Biosciences, Inc. and inventors on patent US9909167. D.P., C.M.S., and G.P.N. are inventors on pending patent US62971722, filed by Stanford University. C.M.S. is a scientific advisor to Enable Medicine, LLC. Y.H.K. received research funding from Merck & Co. The other authors declare no competing interests.
Funding Statement
This work was supported by the National Institutes of Health (NIH) 2U19AI057229-16, 5P01HL10879707, 5R01GM10983604, 5R33CA18365403, 5U01AI101984-07, 5UH2AR06767604, 5R01CA19665703, 5U54CA20997103, 5F99CA212231-02, 1F32CA233203-01, 5U01AI140498-02, 1U54HG010426-01, 5U19AI100627-07, 1R01HL120724-01A1, R33CA183692, R01HL128173-04, 5P01AI131374-02, 5UG3DK114937-02, 1U19AI135976-01, IDIQ17X149, 1U2CCA233238-01, 1U2CCA233195-01 (G.P.N.), F32CA233203 (D.P.), T32AR007422 (D.P.), T32AI007290 (G.L.B.); The National Cancer Institute: U01CA154967 and UM1CA154967 (M.A.C., S.P.F.); Cancer Center Support Grant P30 CA015704. The Department of Defense (W81XWH-14-1-0180 and W81XWH-12-1-0591) (G.P.N.); The Food and Drug Administration (HHSF223201610018C and DSTL/AGR/00980/01) (G.P.N.); Cancer Research UK (C27165/A29073) (G.P.N.); The Bill and Melinda Gates Foundation (OPP1113682) (G.P.N.); The Cancer Research Institute (G.P.N.); The Parker Institute for Cancer Immunotherapy (G.P.N.); The Kenneth Rainin Foundation (2018-575) (G.P.N.); Celgene, Inc. (133826 and 134073) (G.P.N.); the Rachford & Carlotta A. Harris Endowed Chair (G.P.N.); and The Beckman Center for Molecular and Genetic Medicine (D.P., C.M.S., Y.H.K, G.P.N.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of human tissues for this research was fully de-personalized and approved by the Stanford University IRB Administrative Panels on Human Subjects in Medical Research (HSR 46894).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data generated or analyzed in this study are included in this Medrxiv article or available upon reasonable request.
